Localizing Chemotherapeutic Drug Release to Treat Stage III Colorectal Cancer by Sebastian, Ria et al.
Anthony Atalla, Morgan Coley, Matthew Hamers, Nima Karodeh, Jennifer McGrath, Eva Minahan, 
Matthew Nagler, Yomna Nassar, Alison Nichols, Ria Sebastian, Matthew Tiberino, Kevin Wendeu-Foyet
Localizing Chemotherapeutic Drug Release to Treat Stage III Colorectal Cancer




  Research Questions
jhkk
Surgical Sealant Morphology Chemotherapeutic Drug Release 
Approach 
● Colon cancer has a 33% recurrence rate despite aggressive 
treatment 
● Treatment typically includes surgical resection followed by 
systemic chemotherapy, which has adverse side effects.3
● Sutures could be supplemented by a polymer surgical 
sealant to localize treatment
● How can we use a surgical sealant to provide localized 
chemotherapy and mitigate systemic side effects?
● How can we examine the effects of chemotherapeutic drugs 
on surgical sealant properties?
Benefits of SBS: 
Resection
● Permits high degrees of 
freedom and ease of use
Chemotherapy
● Allows direct deposit of 
chemotherapeutic agents at 
resection sites
● Maximizes efficacy of 
treatment while minimizing 
collateral cell damage in the 
body









80kDa PLCL with 
Drug
Capecitabine was soluble in PLCL at both molecular weights. 
When sprayed, incorporation of drug did not alter the ability to 
form fibers or physical properties of the fiber.  
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Solution blow spinning 
(SBS)  involves running a 
dissolved polymer solution 
through an airbrush. The 
solvent evaporates 
rapidly, depositing polymer 
















80 kDa PLCL did not degrade to the extent to which 40 kDa 
PLCL did in physiological conditions within a 60 day period. 
The increase in mass within the 12 week period was 
attributed to water uptake by the polymer. The degradation 
occurred complementary to the wound healing timeline.
Both 40 and 80 kDa PLCL and capecitabine exhibited a 
delayed release profile. Chemotherapy begins 1 week 
to 2 months after surgical resection.2 The start of 
significant drug release begins in both molecular 
weights within this time period. 
Future Directions
The chemotherapeutic did not affect the mechanical 
and physical properties of the surgical sealant. This 
demonstrates that its function as a surgical sealant may 
not be altered by drug incorporation. These fiber mats 
exhibit a delayed release, which indicates possible 
implications in cancer treatment via surgical resection. 
This release pattern complements the normal waiting 
period2 by allowing intestinal healing to occur before 
post-operative chemotherapeutic treatment.
Other biodegradable synthetic polymers will be 
tested to determine if similar drug release patterns are 
observed. This may provide insight into the 
mechanisms behind the delayed release in PLCL trials. 
Pull-off adhesion testing will also be performed to 
further assess the mechanical strength of different 
polymers. These studies will allow us to determine the 
drug-release properties of the polymers in order to 
develop a functional drug delivery system.
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